Moderna’s cancer shot: exciting for investors, inconclusive for patients
A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns
President Donald Trump has a claim to one of the technologies that his movement sometimes criticizes. On Wednesday, Moderna shares rose sharply after the company and Merck announced a successful Phase 3 melanoma trial for their personalized mRNA cancer treatment. This marks the first positive Phase 3 result for an individualized mRNA-based cancer treatment.
Investors responded positively, with Moderna shares jumping around 100% in premarket trading and Merck shares increasing by over 8%. The scientific achievement could be a win for Trump, but it also complicates Robert F. Kennedy Jr. and the Make America Healthy Again movement, as Trump's relationship with mRNA is more favorable than his vaccine politics suggest.
Written by urgent.news from Newsweek's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
